Immunology superstar Dupixent, which first brought Regeneron and Sanofi together in 2007, has entered its megablockbuster era. But even as the billions pile up, Regeneron isn't entirely happy with ...

Covalent bonding is a widely understood phenomenon that joins the atoms of a molecule by a shared electron pair. But in ...

Bristol Myers Squibb has continued its ruthless cost-cutting push, dropping plans to commercialize a rival to Dupixent despite meeting its phase 3 goals and pumping the brakes on a would-be ...

Despite Eylea's market challenges, Dupixent's strong performance and future potential in COPD, along with a robust pipeline, position Regeneron for recovery in 2025. Regeneron's solid financials ...

Chromatin, the mix of DNA and protein that houses each cell's genome, is more resilient to aging than previously thought, suggests a study published in the Journal of the American Chemical Society by ...

Researchers have profiled the molecular structure and features of a key part of the deadly Nipah virus. Experiments in cells showe how changes in the viral polymerase -- a protein involved in ...

Structures are one of the most interesting features in Minecraft. They are generated in various biomes and are different in sizes, shapes, blocks, and mob spawns. When you first enter a new world ...

The CEO discussed the success of Dupixent and the remarkable achievement of over $13 billion in global sales in 2024, highlighting its commercial advantage and setting a milestone for Sanofi.

Among other topics, Hudson discussed the success of Dupixent (dupilumab), highlighting that it has reached over $13bn in global sales, which affirms its commercial advantage and sets a milestone ...

Sanofi and Regeneron have celebrated a pair of positive clinical trials in inflammatory skin disorders with blockbuster immunology therapy Dupixent that could both lead to new indications for the ...

One primary reason is the strong performance and potential of Dupixent, which is expected to partially counterbalance the uncertainties surrounding Eylea. The expected growth in Dupixent’s ...